Expertise: Reducing The Time and Effort to Open Clinical Trials
We have shown that the successful enrollment of a trial is significantly impacted by the time required to open the trial. With this in mind, we work with organizations to identify barriers, eliminate them, and develop plans for reducing time to open a trial. One of our clients has been able to cut the time to open a trial by 50% with our help.
Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
Other Work Related to Reducing The Time and Effort to Open Clinical Trials
1. Cheng S, Dietrich M, Dilts DM (2011) “Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials,” Clin Cancer Res. 17: 1947-55. PMID:21447723
2. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
3. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
4. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
5. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
6. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
7. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
8. Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
9. Dilts DM, (2010) “US cancer trials may go the way of the Oldsmobile,” Nature Medicine 16(5):21. PMID:20526311
10. Dilts DM, (2010) “An Early Warning: Ailing Canary in the Mine,” J Clin Onc, 28(24): 3799-800. PMID: 20644096
11. Kitterman D, Cheng SK, Dilts DM, Orwoll ES (2011) “An etiologic survey of factors that contribute to non-enrolling clinical studies,” NCRR Clinical Research Management Workshop, Bethesda MD (Jun)
12. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
13. Dilts DM, Massett H (2010) Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial”. American Society of Clinical Oncology, Chicago, IL. (Abstract #e16505)
14. Cheng S, Dietrich, M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts DM (2009) “A Sense of Urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies,” J Clin Oncol 27:15s (suppl; abstr 6509)
15. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Are Cancer Clinical Trials in the USA Going the Way of Oldsmobile?,” Production and Operations Management Society 2008.
16. (2015) “Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH,(June).
17. (2015) “Going Beyond the Norm: Some Ideas for the British Columbia Cancer Agency” British Columbia Cancer Agency Retreat, Vancouver, BC(May)
18. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
19. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
2. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
3. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
4. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
5. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
6. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
7. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
8. Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
9. Dilts DM, (2010) “US cancer trials may go the way of the Oldsmobile,” Nature Medicine 16(5):21. PMID:20526311
10. Dilts DM, (2010) “An Early Warning: Ailing Canary in the Mine,” J Clin Onc, 28(24): 3799-800. PMID: 20644096
11. Kitterman D, Cheng SK, Dilts DM, Orwoll ES (2011) “An etiologic survey of factors that contribute to non-enrolling clinical studies,” NCRR Clinical Research Management Workshop, Bethesda MD (Jun)
12. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
13. Dilts DM, Massett H (2010) Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial”. American Society of Clinical Oncology, Chicago, IL. (Abstract #e16505)
14. Cheng S, Dietrich, M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts DM (2009) “A Sense of Urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies,” J Clin Oncol 27:15s (suppl; abstr 6509)
15. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Are Cancer Clinical Trials in the USA Going the Way of Oldsmobile?,” Production and Operations Management Society 2008.
16. (2015) “Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH,(June).
17. (2015) “Going Beyond the Norm: Some Ideas for the British Columbia Cancer Agency” British Columbia Cancer Agency Retreat, Vancouver, BC(May)
18. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
19. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)